Xiaojuan B. Chen
NHC Key Laboratory Of Cancer Proteomics & State Local Joint Engineering Laboratory For Anticancer Drugs
Changsha, 410008, China
Changsha, 410008, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 50 publications
Structure-Based Design and Optimization of Novel, Potent and Selective Covalent FGFR2/3 Inhibitors with a Tricyclic Core.
Journal: Journal of medicinal chemistry
Published: June 08, 2026
Cost-effectiveness of fuzuloparib, with or without apatinib, for BRCA mutation HER2-negative metastatic breast cancer in China.
Journal: Frontiers in pharmacology
Published: April 24, 2026
Structure-Based Design of 4-(1-Methyl-1H-indol-3-yl)pyrimidin-2-amine Derivatives as the First Covalent FGFR3 Selective Inhibitors.
Journal: Journal of medicinal chemistry
Published: February 06, 2026
Design, Synthesis, and Biological Evaluation of the First Novel Macrocycle-Based FGFR Inhibitors That Overcome Clinically Acquired Resistance.
Journal: Journal of medicinal chemistry
Published: January 06, 2026
Design, Synthesis and Biological Evaluation of 7-(1-Methyl-1H-indole-3-yl)-5H-pyrrolo[2,3-b]pyrazine Derivatives as Novel Covalent pan-FGFR Inhibitors to Overcome Clinical Resistance.
Journal: Journal of medicinal chemistry
Published: September 08, 2025
FOXC2 represses NFAT1-dependent transcription through a DNA-facilitated protein-protein interaction.
FOXC2 represses NFAT1-dependent transcription through a DNA-facilitated protein-protein interaction.
Journal: Nucleic acids research
Published: September 01, 2025
Design, synthesis and biological evaluation of the activity-based probes for FGFR covalent inhibitor.
Journal: European journal of medicinal chemistry
Published: March 04, 2025
Optimization of Aminoindazole derivatives as highly selective covalent inhibitors for wild-type and mutant FGFR4.
Journal: Bioorganic chemistry
Published: February 27, 2025
Cadonilimab plus chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancer: a cost-effectiveness analysis.
Journal: Frontiers in immunology
Published: January 18, 2025
Integrative Multi-Omics Approaches Reveal Selectivity Profiles and Molecular Mechanisms of FIIN-2, a Covalent FGFR Inhibitor.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: October 08, 2024
Characterization of Bozitinib as a potential therapeutic agent for MET-amplified gastric cancer.
Journal: Communications biology
Published: August 08, 2024
Deciphering molecular specificity in MCL-1/BAK interaction and its implications for designing potent MCL-1 inhibitors.
Journal: Cell death and differentiation
Published: July 08, 2024
Last Updated: 09/26/2026